Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Roche's Guide To Success In Oncology

Executive Summary

Roche's potential in the growing field of immuno-oncology has been a game of wait and see. But now that Tecentriq has launched, the company believes the components are in place to maintain its leadership position in oncology.

Advertisement

Related Content

How Immuno-Oncology Is Turning Biomarker Development On Its Head
PDUFA VI: A Machine To Speed R&D Time, Cut Costs
Roche Sees Cancer Combos Start To Deliver
Bristol Pushes Pedal To Metal In Immuno-Oncology Combo Testing
Engineering Roche’s Next Big Thing: Bispecific Antibodies And Beyond
For Roche Immuno-Oncology, It’s Steady As She Goes
Pharma trial needs drive Roche's $1.2bn Foundation Medicine deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register